Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)

Next Previous
Search
Trial Profile

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dotinurad (Primary) ; Benzbromarone
  • Indications Hyperuricaemia
  • Focus Therapeutic Use
  • Sponsors Fuji Yakuhin

Most Recent Events

  • 15 Nov 2021 Results of systematic review and meta-analysis of randomized controlled trials (NCT02416167, NCT03100318, NCT03372200 ) were published in the International Journal of Clinical Pharmacology and Therapeutics.
  • 24 Sep 2018 Status changed from active, no longer recruiting to completed.
  • 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top